ClinicalTrials.gg
RecruitingNCT04847752Updated Jun 20, 2024

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

An observational study in Ischemic Stroke and Large-Artery Atherosclerosis (Embolus/Thrombosis), sponsored by Tongji Hospital. Recruiting at 1 site in China. Open to participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Tongji Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
Up to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
65th of 188
1,000 · median 625
Started
2021
with 54 others
Observational
188 of 754
108 open now
Primary completion
2026-12
later than 153 of 399 live
Registered
205th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 65th largest by planned enrollment of the 188 observational ones that give a count, is one of 55 that started in 2021, is one of 188 observational ones, reaches primary completion later than 153 of the 399 other live ones, and was the 205th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: Up to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This is a single-center prospective cohort study of predictive factors related to prognosis of ischemic stroke due to large-artery atherosclerosis.

From March 1, 2021 to December 31, 2026, 1000 patients with ischemic stroke due to large-artery atherosclerosis who are admitted to the Department of Neurology or Neurosurgery, Tongji Hospital are going to be recruited. Detailed clinical data in emergency room and in-hospital will be obtained from the medical record reviews, and the National Institutes of Health Stroke Scale (NIHSS) and Modified Rankin Scale (mRS) score will be done by certified neurologists to assess the severity of the disease in acute stage and treatment outcome during the follow-up. All cases will undergo routine blood tests, brain magnetic resonance imaging (MRI) and cerebral vascular examination, such as TCD, CTA, HRMR or DSA. The investigators will analyze the in-hospital factors that could predict the outcome to provide more evidence-based suggestions in the treatment and prognosis of atherosclerotic ischemic cerebrovascular disease.

Read the detailed description

The detaited information about this trial is described below

  1. Quality assurance: The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
  2. Data check: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data.
  3. Source data verification: Medical records, electronic case report forms, and imaging would be processed by certified neurologists.
  4. Data included:

    4.1 Baseline Variables: NIHSS and mRS scores before ischemic stroke 4.2 In-hospital Variables: 4.2.1 Main symptoms(1=facial paralysis 2=limb weakness 3=limb numbness 4=facial numbness 5=lalopathy 6=ataxia 7=dysphagia 8=bulbar paralysis 9=dizziness 10=nausea and vomit 11=vision disorder 12=confusion 13=headache 14=unconsciousness 15=others) NIHSS and mRS scores after admission 4.2.2 Brain CT and ASPECT scores 4.2.3 DWI 4.2.4 CTA, MRA, DSA, carotid artery ultrasound andTCD to evaluate the stenosis degree of large vessels 4.2.5 HRMR to evaluate the changes of the plaque of intracranial stenosis 4.2.6 Blood routine tests 4.2.7 HbALc and FBG 4.2.8 LDL HDL ApoA1 and ApoB 4.2.9 Cardiac TnI and NT-proBNP 4.2.10 Proteomic analysis of fresh plasma 4.2.11 Histopathological tissues and transcriptomics of CEA

  5. Standard Operating Procedures 5.1 Patient recruitment: From March 1, 2021 to December 31, 2026, 1000 patients with ischemic stroke due to large-artery atherosclerosis who are admitted to the Department of Neurology and Neurosurgery, Tongji Hospital are going to be recruited 5.2 Data collection: Detailed clinical data in emergency room and in-hospital will be obtained from the medical record reviews, and the National Institutes of Health Stroke Scale (NIHSS) and Modified Rankin Scale (mRS) score will be done by certified neurologists to assess the severity of the disease in acute stage and clinical outcome during the follow-up. All cases would undergo routine blood tests, brain magnetic resonance imaging (MRI) and cerebral vascular examination, such as TCD, CTA, HRMR or DSA.

    5.3 Data management, The research data is reviewed by an Independent Research Panel.

    5.4 Data analysis: Biostatisticians from the Department of Neurology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology will conduct statistical analysis

  6. Sample size assessment: About 1000 cases.
  7. Plan for missing data: The number of lost cases will be treated as the deleted value and the lost rate will be indicated. Complete sample intentionality analysis and intent-to-treat (ITT) analysis would be performed on the end points. During the analysis, if there is a statistical difference in the results, the number of participants lost in the exposed group will be deleted, and the number of participants lost to in the non-exposed group will be added. If there is still a statistical difference in the results, the loss of follow-up will not have an impact on the analysis results of this group.
  8. Statistical analysis: All statistical data would be analyzed by the SPSS Software 24.0 version. Continuous variables would be reported as median (range, minimum-maximum), which would be compared by Mann-Whitney test, and categorical data would be represented as percentages and frequencies, which would be compared by the two-tailed Fisher's exact test or one-way ANOVA. P\<0.05 would be considered statistically significant.
03

Conditions studied

  • Ischemic Stroke
  • Large-Artery Atherosclerosis (Embolus/Thrombosis)
04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with ischemic stroke due to large-artery atherosclerosis admission to Department of Neurology and Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from March 1, 2021 - December 31, 2026

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ischemic stroke due to large-artery atherosclerosis has been proved by clinical symptoms and imaging examinations.
  • Symptomatic superior arch stenosis >50%
  • Asymptomatic superior arch stenosis was >70%
  • written was obtained from patients or their surrogates before enrollment.

Exclusion criteria

Exclusion Criteria:

  • Brain CT or MRI showing cerebral hemorrhage (excluded ischemic stroke with hemorrhage transformation)
  • With severe systemic disease, are expected to survive \< 3 months
  • Patients will not able to provide continuous follow-up information
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • Procedurecarotid artery stenting

    common treatments for carotid artery stenosis

    Also known as: CAS

  • Procedurecarotid endarterectomy

    common treatments for carotid artery stenosis

    Also known as: CEA

  • the dosage and duration

    Also known as: ASP

  • the dosage and duration

    Also known as: plavix

  • DrugAnticoagulant

    the dosage and duration

    Also known as: warfarin, rivaroxaban, dabigatran, any other anticoagulant therapy

  • DrugStatinsStudies of StatinsStatins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    the dosage and duration

    Also known as: atorvastatin, rosuvastatin, any other statin drugs

  • the dosage and duration

    Also known as: Evolocumab, Alirocumab, any other PCSK9 inhibitors

06

What researchers measure

Primary outcomes

  1. all-cause mortality

    Death during the follow-up in every single reason

    Time frame: 3-6 months after onset.

  2. Stroke of any kind

    Brain CT or MRI scans will be used to measure whether there is any kind of stroke, including TIA, ischemic stroke, and hemorrhage

    Time frame: 3-6 months after onset.

Secondary outcomes

  1. Rehospitalization

    The rehospitalized times of any circumstances except for admission to hospital only for examination per year will be used to measure the situation

    Time frame: 1 month to 24 months after onset.

  2. National Institute of Health stroke scale (NIHSS score)

    The minimum value is 0, and maximum value is 42, and higher scores mean a worse outcome.

    Time frame: 1 month to 24 months after onset.

  3. modified Ranking score (mRS)

    The minimum value is 0, and maximum value is 6, and higher scores mean a worse outcome.

    Time frame: 1 month to 24 months after onset.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan

Time frame: starting 12 months after publication

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 69 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 69 months is above that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2021
First posted
Apr 19, 2021
StartActual
Mar 1, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04847752
Lead sponsor
Tongji Hospital
Responsible party
Daishi Tian (Prof., Tongji Hospital) — Principal investigator
First posted
Apr 19, 2021
Start date
Mar 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jun 20, 2024

Study contacts

Dai-Shi Tian, Dr.
Contact
tiands@tjh.tjmu.edu.cn
86-27-83663337
Chuan Qin, Dr.
Contact
qinchuan712@126.com
86-27-83663337
Dai-Shi Tian, Dr.
study chair · Tongji Hospital
Chuan Qin, Dr.
principal investigator · Tongji Hospital
Jun Xiao, Dr.
principal investigator · Tongji Hospital
Ke Shang, Dr.
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion